Business Description
AFT Pharmaceuticals Ltd
ISIN : NZAFTE0001S4
Total Employee Number:
126Compare
Compare
Traded in other countries / regions
AFT.New ZealandAFP.Australia IPO Date
2015-12-22Description
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.19 | |||||
Equity-to-Asset | 0.51 | |||||
Debt-to-Equity | 0.49 | |||||
Debt-to-EBITDA | 1.95 | |||||
Interest Coverage | 7.77 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 4.47 | |||||
Beneish M-Score | -1.85 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 17.2 | |||||
3-Year EBITDA Growth Rate | 11.3 | |||||
3-Year EPS without NRI Growth Rate | 11.9 | |||||
3-Year Book Growth Rate | 14.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 27.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 15.32 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 85.97 | |||||
9-Day RSI | 71.45 | |||||
14-Day RSI | 63.97 | |||||
3-1 Month Momentum % | 8.82 | |||||
6-1 Month Momentum % | 13.51 | |||||
12-1 Month Momentum % | 46.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.24 | |||||
Quick Ratio | 1.12 | |||||
Cash Ratio | 0.15 | |||||
Days Inventory | 152.24 | |||||
Days Sales Outstanding | 79.5 | |||||
Days Payable | 69.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.64 | |||||
Dividend Payout Ratio | 0.13 | |||||
Forward Dividend Yield % | 0.64 | |||||
5-Year Yield-on-Cost % | 0.64 | |||||
Shareholder Yield % | -2.82 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 42.61 | |||||
Operating Margin % | 6.86 | |||||
Net Margin % | 5.86 | |||||
EBITDA Margin % | 11.06 | |||||
FCF Margin % | -7.68 | |||||
OCF Margin % | -3.8 | |||||
ROE % | 14.39 | |||||
ROA % | 7.91 | |||||
ROIC % | 7.83 | |||||
3-Year ROIIC % | -0.84 | |||||
ROC (Joel Greenblatt) % | 30.7 | |||||
ROCE % | 19.12 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 27.93 | |||||
Forward PE Ratio | 20.8 | |||||
PE Ratio without NRI | 27.93 | |||||
Shiller PE Ratio | 71.76 | |||||
Price-to-Owner-Earnings | 38.33 | |||||
PEG Ratio | 2.2 | |||||
PS Ratio | 1.63 | |||||
PB Ratio | 3.72 | |||||
Price-to-Tangible-Book | 8.89 | |||||
EV-to-EBIT | 18.79 | |||||
EV-to-Forward-EBIT | 14.18 | |||||
EV-to-EBITDA | 16.29 | |||||
EV-to-Forward-EBITDA | 13.07 | |||||
EV-to-Revenue | 1.8 | |||||
EV-to-Forward-Revenue | 1.41 | |||||
EV-to-FCF | -23.46 | |||||
Price-to-GF-Value | 0.94 | |||||
Price-to-Projected-FCF | 3.13 | |||||
Price-to-Median-PS-Value | 0.58 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.2 | |||||
Price-to-Graham-Number | 3.34 | |||||
| Price-to-Net-Current-Asset-Value | 9.78 | |||||
Earnings Yield (Greenblatt) % | 5.32 | |||||
FCF Yield % | -4.71 | |||||
Forward Rate of Return (Yacktman) % | 13.16 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AFT Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NZ$) | 251.194 | ||
| EPS (TTM) (NZ$) | 0.14 | ||
| Beta | 0.5478 | ||
| 3-Year Sharpe Ratio | -0.08 | ||
| 3-Year Sortino Ratio | -0.12 | ||
| Volatility % | 26.88 | ||
| 14-Day RSI | 63.97 | ||
| 14-Day ATR (NZ$) | 0.072689 | ||
| 20-Day SMA (NZ$) | 3.7545 | ||
| 12-1 Month Momentum % | 46.84 | ||
| 52-Week Range (NZ$) | 2.54 - 4 | ||
| Shares Outstanding (Mil) | 104.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AFT Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AFT Pharmaceuticals Ltd Stock Events
| Event | Date | Price (NZ$) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2027 | 2026-11-20 10:30 | In 132 days | ||
| Second quarter earnings results for 2027 | 2026-11-20 09:00 | In 132 days | ||
| General meeting for 2026 | 2026-07-31 10:30 | In 20 days | ||
| NZD 0.025000 Cash Dividend | 2026-06-18 | 3.85 (+0.26%) | ||
| Fourth quarter earnings conference call for 2026 | 2026-05-21 10:30 | 3.53 (+2.32%) | ||
| Fourth quarter earnings results for 2026 | 2026-05-21 09:00 | 3.53 (+2.32%) | ||
| Annual report for 2026 | 2026-05-20 | 3.45 (-0.86%) | ||
| Second quarter earnings conference call for 2026 | 2025-11-20 10:30 | 3.25 (+2.52%) | ||
| Second quarter earnings results for 2026 | 2025-11-20 09:00 | 3.25 (+2.52%) | ||
| General meeting for 2025 | 2025-08-01 10:30 | 2.69 (-1.47%) |
Show
Entries
AFT Pharmaceuticals Ltd Frequently Asked Questions
What is AFT Pharmaceuticals Ltd(NZSE:AFT)'s stock price today?
The current price of NZSE:AFT is NZ$3.91. The 52 week high of NZSE:AFT is NZ$4.00 and 52 week low is NZ$2.54.
When is next earnings date of AFT Pharmaceuticals Ltd(NZSE:AFT)?
The next earnings date of AFT Pharmaceuticals Ltd(NZSE:AFT) is 2026-11-20 Est..
Does AFT Pharmaceuticals Ltd(NZSE:AFT) pay dividends? If so, how much?
The Dividend Yield %  of AFT Pharmaceuticals Ltd(NZSE:AFT) is 0.64% (As of Today), Highest Dividend Payout Ratio of AFT Pharmaceuticals Ltd(NZSE:AFT) was 0.15. The lowest was 0.07. And the median was 0.13. The  Forward Dividend Yield % of AFT Pharmaceuticals Ltd(NZSE:AFT) is 0.64%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on AFT Pharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers